SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 […]
Tag: Nektar Therapeutics
Nektar Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, […]
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, […]
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
– New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis – SAN FRANCISCO, Sept. 25, 2024 /PRNewswire/ […]